Josiah Craver - Sensei Biotherapeutics Principal Finance
| SNSE Stock | USD 0.53 0.07 11.67% |
Executive
Josiah Craver is Principal Finance of Sensei Biotherapeutics
| Address | 1405 Research Boulevard, Rockville, MD, United States, 20850 |
| Phone | 240 243 8000 |
| Web | https://www.senseibio.com |
Josiah Craver Latest Insider Activity
Tracking and analyzing the buying and selling activities of Josiah Craver against Sensei Biotherapeutics stock is an integral part of due diligence when investing in Sensei Biotherapeutics. Josiah Craver insider activity provides valuable insight into whether Sensei Biotherapeutics is net buyers or sellers over its current business cycle. Note, Sensei Biotherapeutics insiders must abide by specific rules, including filing SEC forms every time they buy or sell Sensei Biotherapeutics'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Josiah Craver over two months ago Insider Trading |
Sensei Biotherapeutics Management Efficiency
The company has return on total asset (ROA) of (0.2703) % which means that it has lost $0.2703 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4517) %, meaning that it created substantial loss on money invested by shareholders. Sensei Biotherapeutics' management efficiency ratios could be used to measure how well Sensei Biotherapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of November 26, 2024, Return On Tangible Assets is expected to decline to -0.48. The current year's Return On Capital Employed is expected to grow to -0.51. At present, Sensei Biotherapeutics' Non Currrent Assets Other are projected to decrease significantly based on the last few years of reporting.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Eddie MBA | Lumos Pharma | N/A | |
| MD FAAP | Lumos Pharma | N/A | |
| Matthew Henn | Seres Therapeutics | 49 | |
| Steve Parsons | Scpharmaceuticals | N/A | |
| Caroline Holda | Seres Therapeutics | N/A | |
| Roshan Girglani | Milestone Pharmaceuticals | N/A | |
| Lisa MD | Seres Therapeutics | 65 | |
| Kim Fox | Milestone Pharmaceuticals | N/A | |
| SPHR SHRMSCP | Seres Therapeutics | 52 | |
| Carlo Tanzi | Seres Therapeutics | N/A | |
| David Ege | Seres Therapeutics | 49 | |
| Jeffrey Nelson | Milestone Pharmaceuticals | 43 | |
| John PharmD | Scpharmaceuticals | N/A | |
| RPh Young | Seres Therapeutics | 57 | |
| JD Esq | Seres Therapeutics | 69 | |
| Nishi MD | Eliem Therapeutics | N/A | |
| Michael Hassman | Scpharmaceuticals | N/A | |
| Rachael Nokes | Scpharmaceuticals | 49 | |
| MD MBA | Eliem Therapeutics | 50 | |
| Valerie Morisset | Eliem Therapeutics | 54 | |
| Alpa Parikh | Lumos Pharma | N/A | |
Management Performance
| Return On Equity | -0.45 | ||||
| Return On Asset | -0.27 |
Sensei Biotherapeutics Leadership Team
Elected by the shareholders, the Sensei Biotherapeutics' board of directors comprises two types of representatives: Sensei Biotherapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Sensei. The board's role is to monitor Sensei Biotherapeutics' management team and ensure that shareholders' interests are well served. Sensei Biotherapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Sensei Biotherapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Edward Horst, Chief Officer | ||
| Christopher JD, VP Counsel | ||
| Elisabeth Colunio, VP HR | ||
| Lora Pike, Vice Communications | ||
| Steven Fuller, Chief Officer | ||
| Robert MD, Chief Officer | ||
| Erin Colgan, Chief Officer | ||
| MS MBA, Chief Officer | ||
| Josiah Craver, Principal Finance | ||
| John MBA, CEO President | ||
| MPH MBA, Chief Officer | ||
| MBA MBA, CEO Pres | ||
| FACP MD, Chief Officer |
Sensei Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Sensei Biotherapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.45 | ||||
| Return On Asset | -0.27 | ||||
| Current Valuation | (27.44 M) | ||||
| Shares Outstanding | 25.15 M | ||||
| Shares Owned By Insiders | 34.39 % | ||||
| Shares Owned By Institutions | 8.81 % | ||||
| Number Of Shares Shorted | 194.69 K | ||||
| Price To Book | 0.33 X | ||||
| EBITDA | (33.39 M) | ||||
| Net Income | (34.1 M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Sensei Biotherapeutics is a strong investment it is important to analyze Sensei Biotherapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Sensei Biotherapeutics' future performance. For an informed investment choice regarding Sensei Stock, refer to the following important reports:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sensei Biotherapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. For information on how to trade Sensei Stock refer to our How to Trade Sensei Stock guide.You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sensei Biotherapeutics. If investors know Sensei will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sensei Biotherapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.19) | Return On Assets (0.27) | Return On Equity (0.45) |
The market value of Sensei Biotherapeutics is measured differently than its book value, which is the value of Sensei that is recorded on the company's balance sheet. Investors also form their own opinion of Sensei Biotherapeutics' value that differs from its market value or its book value, called intrinsic value, which is Sensei Biotherapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sensei Biotherapeutics' market value can be influenced by many factors that don't directly affect Sensei Biotherapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sensei Biotherapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Sensei Biotherapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sensei Biotherapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.